# Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/acr/123793) · 2026-11-09 · Medicine
Page: https://themorning.science/story/safety-of-controversial-vasculitis-drug-bolstered-in-dedicated-trial-e7fe8aea92ca4e0a
Kind: research · Impact: medium

## In brief

- Interim results from a prospective trial designed to evaluate the safety of avacopan (Tavneos) in antineutrophil cytoplasmic antibody-associated vasculitis (AAV) were reported from Orlando.
- Coverage describes avacopan as an embattled drug, and the trial was set up specifically to assess its safety.

## Why it matters

Avacopan has faced controversy, so a dedicated prospective safety trial gives clinicians and researchers more systematic safety data than prior evidence alone. Full results will be needed to judge the strength of the reported safety findings.

## Timeline

- 2026-11-09: Interim safety results from the dedicated avacopan trial reported by MedPage Today from the ORLANDO meeting

## Coverage

- [Safety of Controversial Vasculitis Drug Bolstered in Dedicated Trial](https://www.medpagetoday.com/meetingcoverage/acr/123793) — MedPageToday.com - medical news for physicians, 2026-11-09

Tags: vasculitis, avacopan, drug safety, clinical trial, autoimmune disease

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science